Sail Biomedicines

Name

Sail Biomedicines

Legal name

Sail Biomedicines, Inc.

Website

https://www.sail.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• Programmable RNA medicines
• Endless RNA therapeutics
• Targeted nanoparticle delivery
• In vivo CAR-T therapy
• AI-driven drug design

Headquarters

HQ city

Somerville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Marketing channels5 records

Core offering

Sail Biomedicines develops programmable RNA medicines using a proprietary platform that combines Endless RNA (eRNA) circular RNA technology, Targeted Nanoparticles (TNPs) for cell-specific delivery, and generative AI for integrated medicine design. The company is advancing preclinical and clinical-stage therapeutic programs in autoimmune, metabolic, infectious, and rare diseases, with lead programs including an in vivo CD19-targeted CAR-T therapy for autoimmune disease and eRNA vaccine candidates for malaria.

Product overview

Sail Biomedicines operates as a biopharmaceutical company with a platform-based business model. The core Sail Platform combines first-in-class programmable circular RNA technology (Endless RNA™ or eRNA™) with targeted nanoparticles (TNPs) and proprietary generative AI to comprehensively program RNA medicines. Key products include their In Vivo CAR-T platform using eRNA-TNP constructs for autoimmune diseases, their lead CD19-targeted autoimmune disease program, and their malaria eRNA vaccine candidates. The platform enables programmable pharmacology through eRNA and programmable deployment through TNPs, allowing precise delivery of RNA medicines to targeted cell types. The company was founded in October 2023 as a Flagship Pioneering company and is advancing programs in autoimmune, metabolic, infectious, and rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Sail Programmable RNA Medicines Platform Industry-leading platform combining novel Endless RNA (eRNA) circular RNA technology, Targeted Nanoparticles (TNPs), and proprietary generative AI to comprehensively program RNA medicines for both programmable pharmacology and programmable deployment across multiple disease areas.
• In Vivo eRNA-TNP CAR-T Program (CD19-Targeted Autoimmune Disease Program) Lead autoimmune-disease program using CD19-targeted in vivo CAR-T therapy delivered via eRNA and targeted nanoparticles to achieve broad B-cell depletion across blood, spleen, lymph nodes, and bone marrow. Preclinical studies achieved 50–80% transfection rates in T cells and 5,000–10,000 CAR molecules per cell, with the goal of enabling outpatient administration and expanding CAR-T access from thousands to millions of patients.
• Malaria eRNA Vaccine Program

Quantifiable outcome

• 50-80% transfection rates in T cells achieved with CD19-targeted therapy in preclinical studies
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Three partnerships are on record, tiered minor.

• Johns Hopkins Malaria Research InstituteminorStrategic or Co-development Partner · 1 January 2025Collaborators at the Johns Hopkins Malaria Research Institute performed all malaria challenge studies for Sail's eRNA vaccine candidates.
• Cystic Fibrosis FoundationminorStrategic or Co-development Partner · 5 January 2024Sail Biomedicines has a research collaboration with the Cystic Fibrosis Foundation to advance pioneering medicines research.
• Pioneering MedicinesminorStrategic or Co-development Partner · 5 January 2024Sail Biomedicines collaborates with Pioneering Medicines on research initiatives.

Recent moves7 records

Expansion highlights6 records

Direct peers

• Moderna: Moderna is the leading commercial mRNA therapeutics company with approved vaccines and a broad clinical pipeline spanning infectious disease, oncology and rare diseases. It is the most direct comparable to Sail's programmable RNA medicines platform and shares founders-era lineage via Flagship Pioneering.
• BioNTech: BioNTech is a leading mRNA therapeutics company with approved COVID vaccines and a deep clinical pipeline in oncology and infectious disease. It is directly comparable to Sail as an mRNA-platform company pursuing vaccines and cell-therapy-style applications.
• Alltrna: Alltrna is a Flagship Pioneering-founded tRNA therapeutics company developing programmable transfer RNA medicines. It is a direct peer — same ecosystem origin and same template of building RNA medicines for previously undruggable targets.
• Repertoire Immune Medicines: Repertoire Immune Medicines is a Flagship Pioneering-founded immunology company decoding T-cell receptor biology to develop immune medicines. It is directly comparable given Sail's in vivo CAR-T platform focus on programming patients' immune cells inside the body.
• Ampersand Biomedicines: Ampersand is a Flagship Pioneering-founded programmable medicines company developing cell-selective protein mimetics. Comparable due to shared Flagship origin, shared emphasis on programmable pharmacology, and shared goal of tissue-targeted in-body drug programming.
• Metaphore Biotechnologies: Metaphore is a Flagship Pioneering-founded company developing molecular mimics using protein-inspired design. It is comparable as a peer Flagship-programmable-medicines platform with a similar R&D approach of fusing novel payloads with computational protein design.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the leading commercial RNAi therapeutics company with multiple approved siRNA products. Comparable as the dominant incumbent in RNA-based medicines, validating the broader category even though its siRNA mechanism differs from Sail's eRNA.

Emerging players

• Intellia Therapeutics: Intellia is a clinical-stage CRISPR/Cas9 gene editing company using lipid nanoparticle delivery for in vivo editing. Comparable to Sail as a peer in vivo programmable RNA/nucleic-acid medicines with overlap in LNP-based extra-hepatic delivery and autoimmune disease applications.
• Tessera Therapeutics: Tessera is a Flagship Pioneering-founded gene writing company designing and writing therapeutic DNA into the genome. Comparable as a peer programmable nucleic-acid medicines platform with a similar R&D philosophy of in vivo gene-level reprogramming using novel payloads.
• Wave Life Sciences: Wave Life Sciences develops PRISM-platform RNA medicines including siRNA, antisense and RNA editing candidates. Comparable to Sail in targeting RNA as a therapeutic modality and pursing programmable chemistry for diverse indications including rare diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SailBiomeds
• LinkedInlinkedin.com/company/sail-biomedicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sail Biomedicines